BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22727821)

  • 1. A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5).
    Chitneni SK; Bida GT; Dewhirst MW; Zalutsky MR
    Nucl Med Biol; 2012 Oct; 39(7):1012-8. PubMed ID: 22727821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure.
    Dolbier WR; Li AR; Koch CJ; Shiue CY; Kachur AV
    Appl Radiat Isot; 2001 Jan; 54(1):73-80. PubMed ID: 11144255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [(18)F]EF5.
    Eskola O; Grönroos TJ; Forsback S; Tuomela J; Komar G; Bergman J; Härkönen P; Haaparanta M; Minn H; Solin O
    Mol Imaging Biol; 2012 Apr; 14(2):205-12. PubMed ID: 21448777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.
    Chitneni SK; Bida GT; Zalutsky MR; Dewhirst MW
    J Nucl Med; 2014 Jul; 55(7):1192-7. PubMed ID: 24854792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.
    Chitneni SK; Bida GT; Yuan H; Palmer GM; Hay MP; Melcher T; Wilson WR; Zalutsky MR; Dewhirst MW
    J Nucl Med; 2013 Aug; 54(8):1339-46. PubMed ID: 23740105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer.
    Komar G; Seppänen M; Eskola O; Lindholm P; Grönroos TJ; Forsback S; Sipilä H; Evans SM; Solin O; Minn H
    J Nucl Med; 2008 Dec; 49(12):1944-51. PubMed ID: 18997048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5.
    Ziemer LS; Evans SM; Kachur AV; Shuman AL; Cardi CA; Jenkins WT; Karp JS; Alavi A; Dolbier WR; Koch CJ
    Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):259-66. PubMed ID: 12552344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-EF5 PET Is Predictive of Response to Fractionated Radiotherapy in Preclinical Tumor Models.
    Ali R; Apte S; Vilalta M; Subbarayan M; Miao Z; Chin FT; Graves EE
    PLoS One; 2015; 10(10):e0139425. PubMed ID: 26431331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma.
    Koch CJ; Scheuermann JS; Divgi C; Judy KD; Kachur AV; Freifelder R; Reddin JS; Karp J; Stubbs JB; Hahn SM; Driesbaugh J; Smith D; Prendergast S; Evans SM
    Eur J Nucl Med Mol Imaging; 2010 Nov; 37(11):2048-59. PubMed ID: 20585774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice.
    Silvola JM; Saraste A; Forsback S; Laine VJ; Saukko P; Heinonen SE; Ylä-Herttuala S; Roivainen A; Knuuti J
    Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1011-5. PubMed ID: 21372297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo measurement of the hypoxia marker EF5 in Shionogi tumours using (19)F magnetic resonance spectroscopy.
    Hoff MN; Yapp DT; Yung AC; Oliver TS; Kozlowski P
    Int J Radiat Biol; 2008 Mar; 84(3):237-42. PubMed ID: 18300024
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Qian Y; Von Eyben R; Liu Y; Chin FT; Miao Z; Apte S; Carter JN; Binkley MS; Pollom EL; Harris JP; Prionas ND; Kissel M; Simmons A; Diehn M; Shultz DB; Brown JM; Maxim PG; Koong AC; Graves EE; Loo BW
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1183-1192. PubMed ID: 29859786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.
    Laughlin KM; Evans SM; Jenkins WT; Tracy M; Chan CY; Lord EM; Koch CJ
    J Pharmacol Exp Ther; 1996 May; 277(2):1049-57. PubMed ID: 8627516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia in human intraperitoneal and extremity sarcomas.
    Evans SM; Hahn SM; Magarelli DP; Zhang PJ; Jenkins WT; Fraker DL; Hsi RA; McKenna WG; Koch CJ
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):587-96. PubMed ID: 11173159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles.
    Koch CJ; Hahn SM; Rockwell K; Covey JM; McKenna WG; Evans SM
    Cancer Chemother Pharmacol; 2001 Sep; 48(3):177-87. PubMed ID: 11592338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient radiosynthesis of 3'-deoxy-3'-18F-fluorothymidine using electrowetting-on-dielectric digital microfluidic chip.
    Javed MR; Chen S; Kim HK; Wei L; Czernin J; Kim CJ; van Dam RM; Keng PY
    J Nucl Med; 2014 Feb; 55(2):321-8. PubMed ID: 24365651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
    Wang J; Foehrenbacher A; Su J; Patel R; Hay MP; Hicks KO; Wilson WR
    Clin Cancer Res; 2012 Mar; 18(6):1684-95. PubMed ID: 22167409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts.
    Lee J; Siemann DW; Koch CJ; Lord EM
    Int J Cancer; 1996 Jul; 67(3):372-8. PubMed ID: 8707411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeatability of tumour hypoxia imaging using [
    Silvoniemi A; Suilamo S; Laitinen T; Forsback S; Löyttyniemi E; Vaittinen S; Saunavaara V; Solin O; Grönroos TJ; Minn H
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):161-169. PubMed ID: 29075831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of tumour blood flow, [¹⁸F]EF5 and [¹⁸F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy.
    Komar G; Lehtiö K; Seppänen M; Eskola O; Levola H; Lindholm P; Sipilä H; Seppälä J; Grénman R; Solin O; Minn H
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2042-50. PubMed ID: 24898846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.